Clinical trials: Segmental Vitiligo
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04052425
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Vitiligo
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
- Trial name
- NCT04811131
- Testing
- ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment
- Where
- 5 sites in United States
- Volunteers
- 114 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Non-segmental Vitiligo
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it.
- Trial name
- NCT06113328
- Testing
- MK-6194
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 169 people
- Sponsor
- Merck Sharp & Dohme LLC
Active Non-segmental Vitiligo
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks.
- Trial name
- NCT03715829
- Testing
- PF-06651600, PF06700841, narrow-band UVB phototherapy
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 366 people
- Sponsor
- Pfizer
Non-segmental Vitiligo
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
- Trial name
- NCT04487860
- Testing
- AS012
- Where
- 31 sites in United States, India
- Volunteers
- 327 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial)…
- Trial name
- NCT05247489
- Testing
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Where
- 13 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Vitiligo
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
- Trial name
- NCT03468855
- Testing
- ATI-50002 topical solution
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aclaris Therapeutics, Inc.
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04057573
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 76 sites in United States, Bulgaria and 7 more
- Volunteers
- 344 people
- Sponsor
- Incyte Corporation